South Korea
· Delayed Price · Currency is KRW Bridge Biotherapeutics Company Description
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide.
Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis.
Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade.
The company was founded in 2015 and is headquartered in Seongnam, Korea.
| Country | South Korea |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 35 |
| CEO | James Jungkue Lee |
Contact Details
Address: Building B, Innovalley Seongnam, 13486 South Korea | |
| Website | bridgebiorx.com |
Stock Details
| Ticker Symbol | 288330 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| James Jungkue Lee | Chief Executive Officer |
| Sujin Agnes Jung | Chief Operating Officer |